Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 168 articles:
HTML format

Single Articles

    May 2024
  1. MONAGHAN TM, Ugun-Klusek A, Finelli M, Gurnani P, et al
    Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention.
    Gut. 2024;73:1034-1036.

    April 2024
  2. GABRIELS RY, van der Waaij AM, Linssen MD, Dobosz M, et al
    Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
    Gut. 2024 Apr 5:gutjnl-2023-331696. doi: 10.1136/gutjnl-2023-331696.
    PubMed     Abstract available

  3. RIEDER F, Mukherjee PK, Massey WJ, Wang Y, et al
    Fibrosis in IBD: from pathogenesis to therapeutic targets.
    Gut. 2024;73:854-866.
    PubMed     Abstract available

  4. KARMI N, Sun S, Festen EAM, Vich Vila A, et al
    Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease.
    Gut. 2024 Apr 3:gutjnl-2024-332205. doi: 10.1136/gutjnl-2024-332205.

    March 2024
    Inflammatory bowel diseases: are we ready to recommend a preventive diet for infants?
    Gut. 2024;73:559-560.

  6. SCHULZ-KUHNT A, Ruhle K, Javidmehr A, Dobronti M, et al
    ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo.
    Gut. 2024;73:601-612.
    PubMed     Abstract available

    February 2024
  7. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.

  8. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    PubMed     Abstract available

    It is in the matrix: a molecular clue to fibro-stenotic Crohn's disease.
    Gut. 2024 Feb 20:gutjnl-2024-332016. doi: 10.1136/gutjnl-2024-332016.

  10. AN H, Zhong M, Gan H
    Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study.
    Gut. 2024 Feb 15:gutjnl-2024-331904. doi: 10.1136/gutjnl-2024-331904.

    January 2024
  11. GUO A, Ludvigsson J, Brantsaeter AL, Klingberg S, et al
    Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts.
    Gut. 2024 Jan 30:gutjnl-2023-330971. doi: 10.1136/gutjnl-2023-330971.
    PubMed     Abstract available

  12. SUN J, Yao J, Olen O, Halfvarson J, et al
    Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study.
    Gut. 2024 Jan 6:gutjnl-2023-331632. doi: 10.1136/gutjnl-2023-331632.

  13. CHIRIAC MT, Hracsko Z, Gunther C, Gonzalez-Acera M, et al
    IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.
    Gut. 2024;73:282-297.
    PubMed     Abstract available

    December 2023
  14. ERIKSEN C, Danneskiold-Samsoe NB, Moll JM, Myers PN, et al
    Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease.
    Gut. 2023 Dec 16:gutjnl-2023-330677. doi: 10.1136/gutjnl-2023-330677.
    PubMed     Abstract available

  15. MINERVINA AA, Pogorelyy MV, Paysen S, Luening U, et al
    Crohn's-associated invariant T cells (CAITs) recognise small sulfonate molecules on CD1d.
    Gut. 2023;73:205-206.

    November 2023
  16. TUN HM, Peng Y, Massimino L, Sin ZY, et al
    Gut virome in inflammatory bowel disease and beyond.
    Gut. 2023 Nov 10:gutjnl-2023-330001. doi: 10.1136/gutjnl-2023-330001.
    PubMed     Abstract available

  17. ULLRICH KA, Derdau J, Baltes C, Battistella A, et al
    IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells.
    Gut. 2023;72:2081-2094.
    PubMed     Abstract available

    October 2023
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.

    September 2023
  19. MA Y, Zhang X, Xuan B, Li D, et al
    Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis.
    Gut. 2023 Sep 21:gutjnl-2023-330009. doi: 10.1136/gutjnl-2023-330009.
    PubMed     Abstract available

  20. JIANG L, Li JC, Shen L, Tang BS, et al
    Association between inflammatory bowel disease and Alzheimer's disease: multivariable and bidirectional Mendelian randomisation analyses.
    Gut. 2023;72:1797-1799.

  21. CHURCHHOUSE AM, Moffat VE, Selinger CP, Lamb CA, et al
    British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance.
    Gut. 2023;72:1631-1634.

    August 2023
  22. SCHWARZLER J, Zollner A, Dolejsi T, Mayr L, et al
    Inflammatory bowel disease in STAT1 gain-of-function immunodeficiency treated with precision medicine.
    Gut. 2023 Aug 24:gutjnl-2023-330588. doi: 10.1136/gutjnl-2023-330588.

  23. CHETWOOD JD, Paramsothy S, Haifer C, Leong RW, et al
    Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis.
    Gut. 2023 Aug 17:gutjnl-2023-330196. doi: 10.1136/gutjnl-2023-330196.

  24. WAUTERS L, Tito RY, Ceulemans M, Outtier A, et al
    Microbiome variance of the small bowel in Crohn's disease.
    Gut. 2023;72:1626-1628.

    July 2023
  25. BECKER C, Adolph TE
    Disentangling tryptophan metabolism in inflammatory bowel diseases.
    Gut. 2023;72:1235-1236.

  26. LEE JC
    Going deeper: molecular inflammatory scores in IBD.
    Gut. 2023;72:1233-1234.

  27. MICHAUDEL C, Danne C, Agus A, Magniez A, et al
    Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
    Gut. 2023;72:1296-1307.
    PubMed     Abstract available

  28. ARGMANN C, Hou R, Ungaro RC, Irizar H, et al
    Biopsy and blood-based molecular biomarker of inflammation in IBD.
    Gut. 2023;72:1271-1287.
    PubMed     Abstract available

    June 2023
  29. DE BOER NKH, Simsek M, Meijer B, Neurath MF, et al
    Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
    Gut. 2023 Jun 28:gutjnl-2023-329679. doi: 10.1136/gutjnl-2023-329679.
    PubMed     Abstract available

  30. LOPETUSO LR, Deleu S, Godny L, Petito V, et al
    The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
    Gut. 2023 Jun 20:gutjnl-2023-329948. doi: 10.1136/gutjnl-2023-329948.
    PubMed     Abstract available

  31. SCHWARZFISCHER M, Niechcial A, Handler K, Morsy Y, et al
    TiO(2) nanoparticles abrogate the protective effect of the Crohn's disease-associated variation within the PTPN22 gene locus.
    Gut. 2023;72:1101-1114.
    PubMed     Abstract available

  32. MILLET V, Gensollen T, Maltese M, Serrero M, et al
    Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
    Gut. 2023;72:1115-1128.
    PubMed     Abstract available

  33. DANNE C, Michaudel C, Skerniskyte J, Planchais J, et al
    CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
    Gut. 2023;72:1081-1092.
    PubMed     Abstract available

    May 2023
  34. PAL P, Ramchandani M, Banerjee R, Viswakarma P, et al
    Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial).
    Gut. 2023 May 17:gutjnl-2023-329885. doi: 10.1136/gutjnl-2023-329885.
    PubMed     Abstract available

  35. LU H, Zhang C, Wu W, Chen H, et al
    MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
    Gut. 2023;72:882-895.
    PubMed     Abstract available

  36. ZUO L, Kuo WT, Cao F, Chanez-Paredes SD, et al
    Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
    Gut. 2023;72:870-881.
    PubMed     Abstract available

    April 2023
  37. GHATE A, Uhlig HH
    Defective microbial sensing and clearance in perianal Crohn's disease: a role for complement factor B.
    Gut. 2023 Apr 25:gutjnl-2023-329801. doi: 10.1136/gutjnl-2023-329801.

  38. AKHLAGHPOUR M, Haritunians T, More SK, Thomas LS, et al
    Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
    Gut. 2023 Apr 20:gutjnl-2023-329689. doi: 10.1136/gutjnl-2023-329689.
    PubMed     Abstract available

  39. ZHAO J, Chen J, Sun Y, Yuan S, et al
    Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.
    Gut. 2023 Apr 4:gutjnl-2023-329875. doi: 10.1136/gutjnl-2023-329875.

  40. YE BD
    Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?
    Gut. 2023 Apr 4:gutjnl-2023-329506. doi: 10.1136/gutjnl-2023-329506.

  41. HSU NY, Nayar S, Gettler K, Talware S, et al
    NOX1 is essential for TNFalpha-induced intestinal epithelial ROS secretion and inhibits M cell signatures.
    Gut. 2023;72:654-662.
    PubMed     Abstract available

  42. AGRAWAL M, Poulsen G, Colombel JF, Allin KH, et al
    Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study.
    Gut. 2023;72:804-805.

    March 2023
  43. FAYE AS, Jess T
    Antibiotic use and inflammatory bowel disease: number needed to harm? Authors' reply.
    Gut. 2023 Mar 27:gutjnl-2023-329851. doi: 10.1136/gutjnl-2023-329851.

  44. VICH VILA A, Hu S, Andreu-Sanchez S, Collij V, et al
    Faecal metabolome and its determinants in inflammatory bowel disease.
    Gut. 2023 Mar 23:gutjnl-2022-328048. doi: 10.1136/gutjnl-2022-328048.
    PubMed     Abstract available

  45. LAUBE R, Selinger CP, Seow CH, Christensen B, et al
    Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.
    Gut. 2023 Mar 21:gutjnl-2022-329304. doi: 10.1136/gutjnl-2022-329304.
    PubMed     Abstract available

  46. ZHANG E, Nguyen THO, Allen LF, Kedzierski L, et al
    Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.
    Gut. 2023 Mar 6:gutjnl-2022-329136. doi: 10.1136/gutjnl-2022-329136.

  47. ADAMS A, Gupta V, Mohsen W, Chapman TP, et al
    Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.
    Gut. 2023;72:433-442.
    PubMed     Abstract available

  48. PIERRE N, Huynh-Thu VA, Marichal T, Allez M, et al
    Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity.
    Gut. 2023;72:443-450.
    PubMed     Abstract available

    February 2023
    Antibiotic use and inflammatory bowel disease: number needed to harm?
    Gut. 2023 Feb 21:gutjnl-2023-329575. doi: 10.1136/gutjnl-2023-329575.

  50. LEIBOVITZH H, Lee SH, Raygoza Garay JA, Espin-Garcia O, et al
    Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis.
    Gut. 2023 Feb 14:gutjnl-2022-328421. doi: 10.1136/gutjnl-2022-328421.
    PubMed     Abstract available

  51. MASSIMINO L, Palmieri O, Facoetti A, Fuggetta D, et al
    Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo.
    Gut. 2023 Feb 14:gutjnl-2022-328375. doi: 10.1136/gutjnl-2022-328375.
    PubMed     Abstract available

  52. WAGNER F, Mansfield JC, Lekkerkerker AN, Wang Y, et al
    Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.
    Gut. 2023 Feb 2:gutjnl-2022-328387. doi: 10.1136/gutjnl-2022-328387.
    PubMed     Abstract available

  53. BARBERIO B, Gracie DJ, Black CJ, Ford AC, et al
    Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
    Gut. 2023;72:264-274.
    PubMed     Abstract available

  54. KENNEDY NA, Janjua M, Chanchlani N, Lin S, et al
    Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
    Gut. 2023;72:295-305.
    PubMed     Abstract available

  55. LEES CW, Ahmad T, Lamb CA, Powell N, et al
    Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity.
    Gut. 2023;72:410-412.

  56. HAAG LM, Siegmund B
    Epithelial RAC1 niches in IBD: from barrier integrity to cytoskeletal plasticity.
    Gut. 2023;72:219-220.

  57. MARTINEZ-SANCHEZ LDC, Ngo PA, Pradhan R, Becker LS, et al
    Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation.
    Gut. 2023;72:275-294.
    PubMed     Abstract available

    January 2023
  58. ABRAHAMI D, Pradhan R, Yin H, Yanofsky R, et al
    Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study.
    Gut. 2023 Jan 30:gutjnl-2022-328866. doi: 10.1136/gutjnl-2022-328866.
    PubMed     Abstract available

  59. FAYE AS, Allin KH, Iversen AT, Agrawal M, et al
    Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study.
    Gut. 2023 Jan 9:gutjnl-2022-327845. doi: 10.1136/gutjnl-2022-327845.
    PubMed     Abstract available

  60. LIU Q, Cammarota G, Ianiro G
    Evaluating microbial determinants of donor efficacy to translate faecal microbiota transplantation from research to clinical practice.
    Gut. 2023;72:5-7.

  61. ELSON CO
    Adherent invasive Escherichia coli in Crohn's disease: guilt by association?
    Gut. 2023;72:2-3.

  62. BUISSON A, Sokol H, Hammoudi N, Nancey S, et al
    Role of adherent and invasive Escherichia coli in Crohn's disease: lessons from the postoperative recurrence model.
    Gut. 2023;72:39-48.
    PubMed     Abstract available

    December 2022
  63. LOPES EW, Chan SSM, Song M, Ludvigsson JF, et al
    Lifestyle factors for the prevention of inflammatory bowel disease.
    Gut. 2022 Dec 6:gutjnl-2022-328174. doi: 10.1136/gutjnl-2022-328174.
    PubMed     Abstract available

  64. ADOLPH TE, Zhang J
    Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts.
    Gut. 2022;71:2574-2586.
    PubMed     Abstract available

  65. SALAS A
    What good can neutrophils do in UC?
    Gut. 2022;71:2375-2376.

  66. LETT MJ, Mehta H, Keogh A, Jaeger T, et al
    Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells.
    Gut. 2022;71:2526-2538.
    PubMed     Abstract available

    November 2022
  67. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Reply to Newman et al 'Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
    Gut. 2022 Nov 2. pii: gutjnl-2022-328883. doi: 10.1136/gutjnl-2022-328883.

  68. SCHIEPATTI A, Sanders DS, Baiardi P, Caio G, et al
    Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus.
    Gut. 2022;71:2218-2225.
    PubMed     Abstract available

  69. ROSATI E, Rios Martini G, Pogorelyy MV, Minervina AA, et al
    A novel unconventional T cell population enriched in Crohn's disease.
    Gut. 2022;71:2194-2204.
    PubMed     Abstract available

  70. HUO X, Li D, Wu F, Li S, et al
    Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists.
    Gut. 2022;71:2205-2217.
    PubMed     Abstract available

  71. WARD D, Andersson M, Nyboe Andersen N, Allin KH, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study.
    Gut. 2022;71:2373-2374.

    October 2022
  72. NEWMAN KL, Jencks K, Chedid V, Paul S, et al
    Response to Mansoor et al: 'epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
    Gut. 2022 Oct 13. pii: gutjnl-2022-328802. doi: 10.1136/gutjnl-2022-328802.

    September 2022
  73. SUDHAKAR P, Wellens J, Verstockt B, Ferrante M, et al
    Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
    Gut. 2022 Sep 28. pii: gutjnl-2022-328221. doi: 10.1136/gutjnl-2022-328221.
    PubMed     Abstract available

  74. ZOLLER H, Wolf M, Blumenstein I, Primas C, et al
    Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Gut. 2022 Sep 9. pii: gutjnl-2022-327897. doi: 10.1136/gutjnl-2022-327897.
    PubMed     Abstract available

  75. KIRCHGESNER J, Desai RJ, Schneeweiss MC, Beaugerie L, et al
    Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
    Gut. 2022;71:1781-1789.
    PubMed     Abstract available

  76. CANNATELLI R, Ferretti F, Carmagnola S, Bergna IMB, et al
    Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD.
    Gut. 2022;71:1926-1928.

  77. FAIRBRASS KM, Lovatt J, Barberio B, Yuan Y, et al
    Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis.
    Gut. 2022;71:1773-1780.
    PubMed     Abstract available

  78. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Epidemiology of inflammatory bowel disease in men with high-risk homosexual activity.
    Gut. 2022 Sep 1. pii: gutjnl-2022-328218. doi: 10.1136/gutjnl-2022-328218.

    August 2022
  79. KEDIA S, Virmani S, K Vuyyuru S, Kumar P, et al
    Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial.
    Gut. 2022 Aug 16. pii: gutjnl-2022-327811. doi: 10.1136/gutjnl-2022-327811.
    PubMed     Abstract available

  80. RIMOLA J, Torres J, Kumar S, Taylor SA, et al
    Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease.
    Gut. 2022 Aug 4. pii: gutjnl-2021-326562. doi: 10.1136/gutjnl-2021-326562.
    PubMed     Abstract available

  81. GUO X, Chong L, Zhang X, Li R, et al
    Letter to the editor: Genetically determined IBD is associated with decreased risk of Alzheimer's disease: a Mendelian randomisation study.
    Gut. 2022;71:1688-1689.

  82. ADOLPH TE, Siegmund B
    Deciphering the vedolizumab dosing conundrum in IBD: when less is more.
    Gut. 2022;71:1455-1456.

  83. BECKER E, Dedden M, Gall C, Wiendl M, et al
    Residual homing of alpha4beta7-expressing beta1(+)PI16(+) regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.
    Gut. 2022;71:1551-1566.
    PubMed     Abstract available

    July 2022
  84. IACUCCI M, Parigi TL, Bazarova A, Ghosh S, et al
    Response to: Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificia
    Gut. 2022 Jul 27. pii: gutjnl-2022-327980. doi: 10.1136/gutjnl-2022-327980.

  85. XIONG S, Whitehurst CE, Li L, Heo GS, et al
    Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response.
    Gut. 2022;71:1289-1301.
    PubMed     Abstract available

    June 2022
  86. DANESE S, Solitano V, Jairath V, Peyrin-Biroulet L, et al
    The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment).
    Gut. 2022 Jun 14. pii: gutjnl-2022-327025. doi: 10.1136/gutjnl-2022-327025.

  87. WONG ECL, Dulai PS, Narula N
    Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligenc
    Gut. 2022 Jun 7. pii: gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661.

  88. STIDHAM RW, Vickers A, Singh K, Waljee AK, et al
    From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?
    Gut. 2022;71:1046-1047.

  89. KAPLAN GG, Ma C, Charlton C, Kanji JN, et al
    Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.
    Gut. 2022;71:1229-1231.

  90. NARULA N, Wong ECL, Colombel JF, Sandborn WJ, et al
    Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
    Gut. 2022;71:1078-1087.
    PubMed     Abstract available

    May 2022
  91. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.
    Gut. 2022 May 23. pii: gutjnl-2022-327440. doi: 10.1136/gutjnl-2022-327440.

    April 2022
  92. LIN S, Lau LH, Chanchlani N, Kennedy NA, et al
    Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Gut. 2022 Apr 27. pii: gutjnl-2021-326784. doi: 10.1136/gutjnl-2021-326784.
    PubMed     Abstract available

  93. VOSKENS C, Stoica D, Rosenberg M, Vitali F, et al
    Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.
    Gut. 2022 Apr 15. pii: gutjnl-2022-327075. doi: 10.1136/gutjnl-2022-327075.
    PubMed     Abstract available

  94. JESS T, Vestergaard MV, Iversen AT, Allin KH, et al
    Undiagnosed inflammatory bowel disease among individuals undergoing colorectal cancer screening: a nationwide Danish cohort study 2014-2018.
    Gut. 2022 Apr 12. pii: gutjnl-2022-327296. doi: 10.1136/gutjnl-2022-327296.

  95. RAINE T, Pavey H, Qian W, Moran GW, et al
    Establishment of a validated central reading system for ileocolonoscopy in an academic setting.
    Gut. 2022;71:661-664.

  96. JIMENEZ-VARGAS NN, Yu Y, Jensen DD, Bok DD, et al
    Agonist that activates the micro-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
    Gut. 2022;71:695-704.
    PubMed     Abstract available

    March 2022
  97. GORDON IO, Bettenworth D, Bokemeyer A, Srivastava A, et al
    International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease.
    Gut. 2022;71:479-486.
    PubMed     Abstract available

  98. PAGANO E, Elias JE, Schneditz G, Saveljeva S, et al
    Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment.
    Gut. 2022;71:509-520.
    PubMed     Abstract available

    February 2022
  99. GUI X, Bazarova A, Del Amor R, Vieth M, et al
    PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326376. doi: 10.1136/gutjnl-2021-326376.
    PubMed     Abstract available

  100. LI X, Tong X, Wong ICK, Peng K, et al
    Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study.
    Gut. 2022 Feb 8. pii: gutjnl-2021-326860. doi: 10.1136/gutjnl-2021-326860.

  101. MA C, Khanna R, Guizzetti L, Zou G, et al
    Methods for handling missing segments in Crohn's disease clinical trials: analysis from the EXTEND trial.
    Gut. 2022;71:447-448.

  102. LIU Z, Liu X, Liang J, Shi Y, et al
    Unusual cause of bloody stool with earache and saddle-nose deformity.
    Gut. 2022;71:264-356.

    January 2022
  103. SPALINGER MR, Shawki A, Chatterjee P, Canale V, et al
    Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence.
    Gut. 2022;71:89-99.
    PubMed     Abstract available

  104. MAO R, Doyon G, Gordon IO, Li J, et al
    Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease.
    Gut. 2022;71:55-67.
    PubMed     Abstract available

  105. JONGSMA MME, Aardoom MA, Cozijnsen MA, van Pieterson M, et al
    First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Gut. 2022;71:34-42.
    PubMed     Abstract available

    December 2021
  106. BURR NE, Gracie DJ, Black CJ, Ford AC, et al
    Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.
    Gut. 2021 Dec 22. pii: gutjnl-2021-326390. doi: 10.1136/gutjnl-2021-326390.
    PubMed     Abstract available

  107. WELLENS J, Edmans M, Obolski U, McGregor CG, et al
    Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
    Gut. 2021 Dec 15. pii: gutjnl-2021-326312. doi: 10.1136/gutjnl-2021-326312.

  108. LEPPKES M, Lindemann A, Gosswein S, Paulus S, et al
    Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis.
    Gut. 2021 Dec 3. pii: gutjnl-2021-324725. doi: 10.1136/gutjnl-2021-324725.
    PubMed     Abstract available

  109. MCGREGOR CG, Adams A, Sadler R, Arancibia-Carcamo CV, et al
    Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
    Gut. 2021;70:2398-2400.

  110. WELLENS J, Sabino J, Vermeire S
    PPIs and anti-TNF in patients with IBD: a forbidden combination?
    Gut. 2021;70:2397-2398.

  111. NA YR, Jung D, Stakenborg M, Jang H, et al
    Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation.
    Gut. 2021;70:2249-2260.
    PubMed     Abstract available

    November 2021
  112. SHIRE ZJ, Reicherz F, Lawrence S, Sudan H, et al
    Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy.
    Gut. 2021 Nov 23. pii: gutjnl-2021-326196. doi: 10.1136/gutjnl-2021-326196.

  113. CROUWEL F, Buiter HJC, de Boer NKH
    There is still a place for optimised thiopurine therapy in IBD.
    Gut. 2021;70:2207.

    October 2021
  114. ODUFALU FD, Long M, Lin K, Mahadevan U, et al
    Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry.
    Gut. 2021 Oct 22. pii: gutjnl-2021-325317. doi: 10.1136/gutjnl-2021-325317.
    PubMed     Abstract available

  115. ATTAUABI M, Seidelin J, Burisch J
    Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?
    Gut. 2021;70:2020-2022.

  116. KENNEDY NA, Lin S, Goodhand JR, Chanchlani N, et al
    Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Gut. 2021;70:1884-1893.
    PubMed     Abstract available

  117. JUKIC A, Bakiri L, Wagner EF, Tilg H, et al
    Calprotectin: from biomarker to biological function.
    Gut. 2021;70:1978-1988.
    PubMed     Abstract available

    September 2021
  118. KHAN N, Mahmud N, Trivedi C, Reinisch W, et al
    Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
    Gut. 2021;70:1657-1664.
    PubMed     Abstract available

  119. ADEGBOLA SO, Dibley L, Sahnan K, Wade T, et al
    Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's Anal Fistula Quality of Life (CAF-QoL) scale.
    Gut. 2021;70:1649-1656.
    PubMed     Abstract available

  120. KANDIAH K, Subramaniam S, Thayalasekaran S, Chedgy FJ, et al
    Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial).
    Gut. 2021;70:1684-1690.
    PubMed     Abstract available

    August 2021
  121. GORELIK Y, Freilich S, Gerassy-Vainberg S, Pressman S, et al
    Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFalpha therapy in inflammatory bowel disease patients: a report from the epi-IIRN.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325185. doi: 10.1136/gutjnl-2021-325185.
    PubMed     Abstract available

    July 2021
  122. VERSTOCKT B, Boets L, Sabino J, Vermeire S, et al
    Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease.
    Gut. 2021;70:1416-1418.

  123. CARON B, Sandborn WJ, Schreiber S, Panaccione R, et al
    Drug development for ulcerative proctitis: current concepts.
    Gut. 2021;70:1203-1209.

    June 2021
  124. HANSEN R, Meade S, Beattie RM, Auth MK, et al
    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2021;70:1044-1052.
    PubMed     Abstract available

  125. AGRAWAL M, Corn G, Shrestha S, Nielsen NM, et al
    Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study.
    Gut. 2021;70:1037-1043.
    PubMed     Abstract available

    May 2021
  126. CURTIUS K, Kabir M, Al Bakir I, Choi CHR, et al
    Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool.
    Gut. 2021 May 14. pii: gutjnl-2020-323546. doi: 10.1136/gutjnl-2020-323546.
    PubMed     Abstract available

  127. KENNEDY NA, Goodhand JR, Bewshea C, Nice R, et al
    Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Gut. 2021;70:865-875.
    PubMed     Abstract available

  128. AXELRAD JE, Olen O, Sachs MC, Erichsen R, et al
    Reply: Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:998.

  129. GIUFFRIDA P, Vanoli A, Di Sabatino A
    Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:997-998.

    April 2021
  130. BOLTE LA, Vich Vila A, Imhann F, Collij V, et al
    Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.
    Gut. 2021 Apr 2. pii: gutjnl-2020-322670. doi: 10.1136/gutjnl-2020-322670.
    PubMed     Abstract available

  131. Correction: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2021;70:1.

  132. LEES CW, Irving PM, Beaugerie L
    COVID-19 and IBD drugs: should we change anything at the moment?
    Gut. 2021;70:632-634.

  133. SIEGEL CA, Melmed GY, McGovern DP, Rai V, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
    Gut. 2021;70:635-640.

  134. UNGARO RC, Brenner EJ, Gearry RB, Kaplan GG, et al
    Effect of IBD medications on COVID-19 outcomes: results from an international registry.
    Gut. 2021;70:725-732.
    PubMed     Abstract available

  135. ZHAO R, Wan QY, Wu Y, Wang Y, et al
    Crohn's disease instead of UC might increase the risk of small bowel cancer.
    Gut. 2021;70:809-810.

  136. GREUTER T, Rieder F, Kucharzik T, Peyrin-Biroulet L, et al
    Emerging treatment options for extraintestinal manifestations in IBD.
    Gut. 2021;70:796-802.
    PubMed     Abstract available

    March 2021
  137. ASHTON JJ, Ennis S, Beattie RM
    Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease.
    Gut. 2021 Mar 15. pii: gutjnl-2021-324214. doi: 10.1136/gutjnl-2021-324214.

  138. JUZNIC L, Peuker K, Strigli A, Brosch M, et al
    SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation.
    Gut. 2021;70:485-498.
    PubMed     Abstract available

    February 2021
  139. HU S, Vich Vila A, Gacesa R, Collij V, et al
    Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD.
    Gut. 2021;70:285-296.
    PubMed     Abstract available

  140. TAKENAKA K, Kimura M, Ohtsuka K
    Colonic strictures mimicking Crohn's disease.
    Gut. 2021;70:233-387.

    January 2021
  141. D'HAENS GR, van Deventer S
    25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.
    Gut. 2021 Jan 11. pii: gutjnl-2019-320022. doi: 10.1136/gutjnl-2019-320022.
    PubMed     Abstract available

    December 2020
  142. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    PubMed     Abstract available

  143. HE X, Gao J, Peng L, Hu T, et al
    Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
    Gut. 2020 Dec 12. pii: gutjnl-2020-322468. doi: 10.1136/gutjnl-2020-322468.
    PubMed     Abstract available

  144. HAIFER C, Saikal A, Paramsothy R, Kaakoush NO, et al
    Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323581. doi: 10.1136/gutjnl-2020-323581.

  145. PAONE P, Cani PD
    Mucus barrier, mucins and gut microbiota: the expected slimy partners?
    Gut. 2020;69:2232-2243.
    PubMed     Abstract available

    November 2020
  146. DERKINDEREN P, Noble W, Neunlist M, Rolli-Derkinderen M, et al
    Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease.
    Gut. 2020 Nov 17. pii: gutjnl-2020-323482. doi: 10.1136/gutjnl-2020-323482.

  147. KHALOIAN S, Rath E, Hammoudi N, Gleisinger E, et al
    Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn's disease recurrence.
    Gut. 2020;69:1939-1951.
    PubMed     Abstract available

    October 2020
  148. BLACKWELL J, Saxena S, Petersen I, Hotopf M, et al
    Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case-control study.
    Gut. 2020 Oct 27. pii: gutjnl-2020-322308. doi: 10.1136/gutjnl-2020-322308.
    PubMed     Abstract available

  149. LEE HS, Lobbestael E, Vermeire S, Sabino J, et al
    Inflammatory bowel disease and Parkinson's disease: common pathophysiological links.
    Gut. 2020 Oct 16. pii: gutjnl-2020-322429. doi: 10.1136/gutjnl-2020-322429.
    PubMed     Abstract available

  150. KANIS SL, Modderman S, Escher JC, Erler N, et al
    Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Gut. 2020 Oct 12. pii: gutjnl-2019-319129. doi: 10.1136/gutjnl-2019-319129.
    PubMed     Abstract available

  151. ASCHENBRENNER D, Quaranta M, Banerjee S, Ilott N, et al
    Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance.
    Gut. 2020 Oct 9. pii: gutjnl-2020-321731. doi: 10.1136/gutjnl-2020-321731.
    PubMed     Abstract available

  152. STOURNARAS E, Qian W, Pappas A, Hong YY, et al
    Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
    Gut. 2020 Oct 1. pii: gutjnl-2019-320185. doi: 10.1136/gutjnl-2019-320185.
    PubMed     Abstract available

  153. JIJON H, Ueno A, Sharifi N, Leung Y, et al
    Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD.
    Gut. 2020;69:1895-1897.

    September 2020
  154. BEELEN EMJ, van der Woude CJ, de Vries AC
    Intestinal resection rates in Crohn's disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFalpha.
    Gut. 2020;69:1.

  155. KHALILI H, Hakansson N, Chan SS, Chen Y, et al
    Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies.
    Gut. 2020;69:1637-1644.
    PubMed     Abstract available

    August 2020
  156. SEYED TABIB NS, Madgwick M, Sudhakar P, Verstockt B, et al
    Big data in IBD: big progress for clinical practice.
    Gut. 2020;69:1520-1532.
    PubMed     Abstract available

    July 2020
  157. PAPAMICHAEL K, Cheifetz AS, Irving PM
    New role for azathioprine in case of switching anti-TNFs in IBD.
    Gut. 2020;69:1165-1167.

  158. ZUO T, Ng SC
    Authors response: giant oversights in the human gut virome.
    Gut. 2020;69:1358.

  159. SUTTON TDS, Clooney AG, Hill C
    Giant oversights in the human gut virome.
    Gut. 2020;69:1357-1358.

  160. DANESE S, Schabel E, Ainsworth MA, Peyrin-Biroulet L, et al
    Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
    Gut. 2020;69:1157-1161.

  161. ROBLIN X, Williet N, Boschetti G, Phelip JM, et al
    Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Gut. 2020;69:1206-1212.
    PubMed     Abstract available

    June 2020
  162. KOELINK PJ, Bloemendaal FM, Li B, Westera L, et al
    Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.
    Gut. 2020;69:1053-1063.
    PubMed     Abstract available

    May 2020
  163. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.

  164. CLOUGH JN, Omer OS, Tasker S, Lord GM, et al
    Regulatory T-cell therapy in Crohn's disease: challenges and advances.
    Gut. 2020;69:942-952.
    PubMed     Abstract available

  165. KIRCHGESNER J, Nyboe Andersen N, Carrat F, Jess T, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Gut. 2020;69:852-858.
    PubMed     Abstract available

  166. GARG M, Royce SG, Tikellis C, Shallue C, et al
    Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
    Gut. 2020;69:841-851.
    PubMed     Abstract available

    April 2020
  167. PANACCIONE R, Colombel JF, Travis SPL, Bossuyt P, et al
    Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
    Gut. 2020;69:658-664.
    PubMed     Abstract available

  168. BOSSUYT P, Vermeire S, Bisschops R
    Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do.
    Gut. 2020;69:788-789.

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.